-
.jpg)
- SITC 2024_GI-108 포스터
- A first-in-human, open-label, multicenter, phase 1/2a, dose-escalation and expansion study of GI-108, a novel immunocytokine combining anti-CD73-IL2v, in patients with advanced or metastatic solid tumors
-
.jpg)
- 오영민VP, Merck초청 webinar 진행
-
- ASCO 2022 참여
-
.jpg)
- EAACI Congress 2019 구두 발표
- The Novel Long-Acting IgE Trap-Fc Fusion Protein GI301 Elicits Therapeutic Synergy In Combination with Probiotics For The Treatment Of Food Allergy
-
.jpg)
- Microbiome movement drug development summit 2019 구두 발표
- GI-301, a novel long-acting IgE Trap-Fc fusion protein that elicits therapeutic synergy in combination with a microbiome agent for the treatment of food allergy
구독 신청을 작성하시면
지속적인 소식을 받아 보실 수 있습니다.
지속적인 소식을 받아 보실 수 있습니다.